What is Zacks Research’s Forecast for Omnicell Q1 Earnings?

Omnicell, Inc. (NASDAQ:OMCLFree Report) – Equities researchers at Zacks Research upped their Q1 2025 earnings per share estimates for Omnicell in a report released on Thursday, November 14th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.15 per share for the quarter, up from their previous estimate of $0.14. The consensus estimate for Omnicell’s current full-year earnings is $0.74 per share. Zacks Research also issued estimates for Omnicell’s Q2 2025 earnings at $0.18 EPS.

Several other research firms have also recently issued reports on OMCL. Barclays upped their price target on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Bank of America reissued a “neutral” rating and set a $57.00 target price (up from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. Benchmark reissued a “buy” rating and set a $48.00 target price on shares of Omnicell in a research note on Wednesday, October 9th. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Friday. Finally, Craig Hallum upped their price target on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $50.83.

Check Out Our Latest Stock Analysis on OMCL

Omnicell Trading Down 2.0 %

Shares of NASDAQ OMCL opened at $45.67 on Monday. The company has a market cap of $2.12 billion, a PE ratio of -117.10, a P/E/G ratio of 43.97 and a beta of 0.81. Omnicell has a 12-month low of $25.12 and a 12-month high of $55.74. The stock has a 50 day simple moving average of $44.20 and a 200-day simple moving average of $36.89.

Institutional Investors Weigh In On Omnicell

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in Omnicell by 1.4% in the first quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after purchasing an additional 80,312 shares in the last quarter. Pacer Advisors Inc. boosted its holdings in Omnicell by 32.6% in the second quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock worth $56,047,000 after purchasing an additional 508,789 shares in the last quarter. Champlain Investment Partners LLC boosted its holdings in Omnicell by 16.0% in the first quarter. Champlain Investment Partners LLC now owns 1,753,205 shares of the company’s stock worth $51,246,000 after purchasing an additional 241,235 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Omnicell by 0.3% in the second quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock worth $31,955,000 after purchasing an additional 3,570 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in Omnicell by 11,982.3% in the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after purchasing an additional 1,138,921 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

About Omnicell

(Get Free Report)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

See Also

Earnings History and Estimates for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.